WuXi XDC Claims Two-Year Streak as Best CDMO
- WuXi XDC was recognized as the Best CDMO at the World ADC Awards on November 7, 2024.
- This honor reflects the company's strong R&D capabilities and contributions to the ADC industry.
- The consecutive wins highlight WuXi XDC's leadership and integrated approach in advancing bioconjugate technologies.
At the World ADC Awards held on November 7, 2024, WuXi XDC was recognized as the Best CDMO, marking its second consecutive year of receiving this honor. The prestigious awards celebrate achievements in the antibody-drug conjugate (ADC) industry, highlighting innovations in research and development. WuXi XDC was also shortlisted for additional categories, emphasizing its strengths in ADC platform technology and contract research organization services. This recognition reflects the company's commitment to excellence in bioconjugate services, contributing to a significant reduction in development timelines for ADCs, from discovery to clinical trials. The awards ceremony took place during the World ADC San Diego conference, which showcases important advancements in the ADC field. Dr. Jimmy Li, CEO of WuXi XDC, expressed his gratitude and pride in the company's achievements, noting that this award is a testament to the team's dedication to driving innovation. The company has created a unique, integrated CRDMO platform that unifies the various phases of ADC development and manufacturing, enabling quicker transitions from research to market. Over the past three years, WuXi XDC has steadily gained recognition from its peers, as validated by its previous awards in 2023 and 2022. This ongoing success underlines the company's role in meeting diverse client needs while simultaneously maintaining high-quality standards. As WuXi XDC continues to lead in the ADC sector, it remains a key partner for organizations looking to streamline their drug development processes efficiently.